These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 27838867)

  • 1. Safety of raltegravir-based antiretroviral therapy in HIV-infected patients receiving multi-kinase inhibitors.
    Loulergue P; Merad M; Coriat R; Ducreux M; Planchard D; Boige V; Le Cesne A; Gregory TM; Poinsignon V; Paci A; Mir O
    Invest New Drugs; 2017 Apr; 35(2):247-249. PubMed ID: 27838867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of antiretroviral regimens including raltegravir to treat HIV-infected patients with hemophilia.
    Xiao H; Xue Y; Gu S; Wang J; Sun H; Lu H
    Biosci Trends; 2016 Feb; 10(1):42-6. PubMed ID: 26911541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Raltegravir plus two nucleoside analogues as combination antiretroviral therapy in HIV-infected patients who require cancer chemotherapy.
    Casado JL; Machuca I; Bañón S; Moreno A; Moltó J; Rodriguez MA
    Antivir Ther; 2015; 20(7):773-7. PubMed ID: 25879675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Raltegravir Plus Nevirapine as Maintenance Antiretroviral Therapy in HIV-Positive Patients: Safety, Efficacy and Pharmacokinetics.
    Calcagno A; Montrucchio C; Capetti A; Guaraldi G; Cenderello G; Calza L; Lanzafame M; Marinaro L; Tettoni MC; Trentini L; D'Avolio A; Di Perri G; Bonora S
    Curr HIV Res; 2016; 14(1):54-60. PubMed ID: 26415700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age.
    Vera JH; Jackson A; Dickinson L; Else L; Barber T; Mora-Peris B; Back D; Boffito M; Winston A
    HIV Clin Trials; 2015; 16(1):39-42. PubMed ID: 25777188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Predictive factors of clinically significant drug-drug interactions among regimens based on protease inhibitors, non-nucleoside reverse transcriptase inhibitors and raltegravir].
    Cervero M; Torres R; Jusdado JJ; Pastor S; Agud JL
    Med Clin (Barc); 2016 Apr; 146(8):339-45. PubMed ID: 26971988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between first-year virological response to raltegravir and long-term outcomes in treatment-experienced patients with HIV-1 infection.
    Eron JJ; Cooper DA; Steigbigel RT; Clotet B; Yeni P; Strohmaier KM; Rodgers AJ; Barnard RJ; Nguyen BY; Teppler H;
    Antivir Ther; 2015; 20(3):307-15. PubMed ID: 25350973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of raltegravir-containing regimens in antiretroviral-naïve and -experienced individuals in routine clinical practice.
    Jaeckle M; Khaykin P; Haberl A; De Leuw P; Schüttfort G; Stephan C; Wolf T
    Int J STD AIDS; 2016 Nov; 27(13):1170-1179. PubMed ID: 26429890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Similar efficacy and tolerability of raltegravir-based antiretroviral therapy in HIV-infected patients, irrespective of age group, burden of comorbidities and concomitant medication: Real-life analysis of the German 'WIP' cohort.
    Naumann U; Moll A; Schleehauf D; Lutz T; Schmidt W; Jaeger H; Funke B; Witte V
    Int J STD AIDS; 2017 Aug; 28(9):893-901. PubMed ID: 28385065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Creatine kinase elevation in HIV-1-infected patients receiving raltegravir-containing antiretroviral therapy: a cohort study.
    Monteiro P; Perez I; Pich J; Gatell JM; Martínez E
    J Antimicrob Chemother; 2013 Feb; 68(2):404-8. PubMed ID: 23109185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raltegravir in HIV-1-Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy.
    Blonk MI; Colbers AP; Hidalgo-Tenorio C; Kabeya K; Weizsäcker K; Haberl AE; Moltó J; Hawkins DA; van der Ende ME; Gingelmaier A; Taylor GP; Ivanovic J; Giaquinto C; Burger DM; ;
    Clin Infect Dis; 2015 Sep; 61(5):809-16. PubMed ID: 25944344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study.
    Katlama C; Assoumou L; Valantin MA; Soulié C; Duvivier C; Chablais L; Kolta S; Pialoux G; Mercié P; Simon A; Costagliola D; Peytavin G; Marcelin AG;
    J Antimicrob Chemother; 2014 Jun; 69(6):1648-52. PubMed ID: 24535278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of raltegravir on the total and unintegrated proviral HIV DNA during raltegravir-based HAART.
    Nicastri E; Tommasi C; Abbate I; Bonora S; Tempestilli M; Bellagamba R; Viscione M; Rozera G; Gallo AL; Ivanovic J; Amendola A; Pucillo L; Di Perri G; Capobianchi MR; Narciso P
    Antivir Ther; 2011; 16(6):797-803. PubMed ID: 21900711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.
    Calza L; Danese I; Magistrelli E; Colangeli V; Manfredi R; Bon I; Re MC; Conti M; Viale P
    HIV Clin Trials; 2016 Feb; 17(1):38-47. PubMed ID: 26728706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term tolerability and effectiveness of raltegravir in Japanese patients: Results from post-marketing surveillance.
    Kuroishi N; Watananbe A; Sakuma R; Ruzicka DJ; Hara M
    PLoS One; 2019; 14(1):e0210384. PubMed ID: 30625208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Five years' real-life experience with raltegravir in a large HIV centre.
    van Halsema C; Whitfield T; Lin N; Ashton K; Torkington A; Ustianowski A
    Int J STD AIDS; 2016 Apr; 27(5):387-93. PubMed ID: 25931236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virological failure to raltegravir in Spain: incidence, prevalence and clinical consequences.
    Santos JR; Blanco JL; Masiá M; Gutiérrez F; Pérez-Elías MJ; Iribarren JA; Force L; Antela A; Knobel H; Salavert M; López Bernaldo De Quirós JC; Pino M; Paredes R; Clotet B; ;
    J Antimicrob Chemother; 2015 Nov; 70(11):3087-95. PubMed ID: 26490727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study).
    Fabbiani M; Mondi A; Colafigli M; D'Ettorre G; Paoletti F; D'Avino A; Ciccarelli N; Sidella L; Murri R; Fortuna S; Vullo V; Cauda R; De Luca A; Di Giambenedetto S
    Scand J Infect Dis; 2014 Jan; 46(1):34-45. PubMed ID: 24161018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and effectiveness of raltegravir in patients with haemophilia and anti-HIV multidrug resistance.
    Mangiafico L; Perja M; Fusco F; Riva S; Mago D; Gringeri A
    Haemophilia; 2012 Jan; 18(1):108-11. PubMed ID: 21762404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 group O resistance pathway with raltegravir is similar to HIV-1 group M.
    Alessandri-Gradt E; Morgand M; Delaugerre C; Peytavin G; Sellier P; Simon F; Plantier JC
    AIDS; 2015 Jun; 29(10):1271-3. PubMed ID: 26035328
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.